[go: up one dir, main page]

WO2023239892A1 - Composés pour la modulation de cd68 et leurs utilisations - Google Patents

Composés pour la modulation de cd68 et leurs utilisations Download PDF

Info

Publication number
WO2023239892A1
WO2023239892A1 PCT/US2023/024906 US2023024906W WO2023239892A1 WO 2023239892 A1 WO2023239892 A1 WO 2023239892A1 US 2023024906 W US2023024906 W US 2023024906W WO 2023239892 A1 WO2023239892 A1 WO 2023239892A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
alkyl
compound
ring
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/024906
Other languages
English (en)
Inventor
Jean-François Blain
Duane A. Burnett
Christopher J. HOLLER
Gerhard Koenig
James C. Lanter
Ricardo L. SANZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arkuda Therapeutics
Original Assignee
Arkuda Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkuda Therapeutics filed Critical Arkuda Therapeutics
Publication of WO2023239892A1 publication Critical patent/WO2023239892A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • CD68 (SEQ ID NO: 1 or SEQ ID NO: 2); also known as GP110; LAMP4; SCARD1 ) is a heavily glycosylated transmembrane glycoprotein that is highly expressed by human monocytes and tissue macrophages [Holness et al., Blood 81 (6): 1607-13 (1993)]. It is a member of the lysosomal/endosomal-associated membrane protein (LAMP) family of glycoproteins. CD68 primarily localizes to the lysosome/endosome compartment but can also circulate to the cell surface. CD68 is also a member of the family of scavenger receptors.
  • LAMP lysosomal/endosomal-associated membrane protein
  • methods of modulating CD68 comprising contacting CD68 with a compound as disclosed herein, or pharmaceutically acceptable salt thereof, in an amount sufficient to modulate CD68.
  • Figure 1 shows that photoaffinity cross-linking of the target CD68 was competed with Compound 1 .
  • the target was immunoprecipitated via a biotin handle on the photoaffinity ligand, separated on gel and identified with either a fluorescent streptavidin (Strept-700) or an anti-CD68 antibody.
  • the third image shows the overlap between the two signals.
  • Figure 2 shows results of experiments in which the target CD68 was glycosylated, immunoprecipitated via a biotin handle on the photoaffinity ligand, deglycosylated using either EndoH or PNGaseF, separated on gel and identified with either a fluorescent streptavidin (Strept-700) or an anti-CD68 antibody.
  • the third image shows the overlap between the two signals.
  • Figure 3 shows amino acid sequences of CD68.
  • CD68 Provided herein are methods of modulating CD68 by using a compound as disclosed herein. Modulation of CD68 can be assessed using typical biological assays, including those as described in the examples section below. In some cases, the level of CD68 is increased. In some cases, the level of intracellular CD68 is decreased.
  • expression or function of CD68 is increased, compared to a control, by at least 5%, at least 10%, at least 25%, at least 30%, at least 40%, at least 50%, at least 75%, at least 90%, at least 100%, at least 125%, at least 150%, or at least 200%.
  • expression or function of CD68 is decreased, compared to a control, by at least 5%, at least 10%, at least 25%, at least 30%, at least 40%, at least 50%, at least 75%, at least 90%, at least 100%, at least 125%, at least 150%, or at least 200%.
  • Amount and/or function of CD68 can be assessed using typical biological assays understood in the art (e.g., immunoblot, quantitative RT-PCR).
  • the disclosure further provides methods of treating a CD68-associated disorder in a subject in need thereof comprising administering a therapeutically effective amount of a compound as disclosed herein to a subject in need thereof.
  • the CD68-associated disorder is osteoporosis, cancer, rheumatoid arthritis, lupus, inflammatory bowel disease, chronic liver injury, a wound, malaria, septic shock, or atherosclerosis.
  • the cancer is melanoma, glioma, breast cancer, ovarian cancer, bladder cancer, colorectal cancer and non-small cell lung cancer.
  • the disclosure additionally provides methods of treating additional disorders comprising administering a therapeutically effective amount of a compound as disclosed herein to a subject in need thereof.
  • the additional disorders contemplated by the disclosure include, without limitation, progranulin-associated disorders.
  • the progranulin-associated disorder in various embodiments, is Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), Frontotemporal dementia -Granulin subtype (FTD-GRN), Lewy body dementia (LBD), Prion disease, Motor neuron diseases (MND), Huntington’s disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA), a lysosomal storage disease, nephropathy, a disease associated with inclusions and/or misfunction of C9orf72, TDP-43, FUS, UBQLN2, VCP, CHMP2B, and/or MAPT, an acute neurological disorder, glioblastoma, or neuroblastoma.
  • AD Alzheimer’s disease
  • PD Parkinson’s disease
  • ALS Amyotrophic lateral
  • the lysosomal storage disease is Paget’s disease, Gaucher’s disease, Nieman’s Pick disease, Tay-Sachs Disease, Fabry Disease, Pompe disease, or Naso-Hakula disease.
  • the acute neurological disorder is stroke, cerebral hemorrhage, traumatic brain injury or head trauma.
  • the disorder is Frontotemporal dementia (FTD).
  • the term "subject” refers to any animal (e.g., a mammal), including, but not limited to, humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. Preferably, the subject is a human.
  • the terms "effective amount” or “therapeutically effective amount” refer to that amount of a compound or pharmaceutical composition described herein that is sufficient to effect the intended application including, but not limited to, disease treatment, as described herein. In some embodiments, the amount is that effective for detectable killing or inhibition of the growth or spread of cancer cells; the size or number of tumors; or other measure of the level, stage, progression or severity of the cancer. In some embodiments, the amount is that effective for alleviating, reducing or eliminating an inflammatory condition.
  • the therapeutically effective amount can vary depending upon the intended application, or the subject and disease condition being treated, e.g., the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the weight and age of the patient, which can readily be determined by one of ordinary skill in the art.
  • the term also applies to a dose that will induce a particular response in target cells.
  • the specific dose will vary depending on, for example, the particular compounds chosen, the species of subject and their age/existing health conditions or risk for health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
  • treatment refers to a method of reducing, delaying or ameliorating such a condition before or after it has occurred.
  • Treatment may be directed at one or more effects or symptoms of a disease and/or the underlying pathology.
  • Treatment is aimed to obtain beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disorder.
  • the pharmaceutical compounds and/or compositions can be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • the treatment can be any reduction and can be, but is not limited to, the complete ablation of the disease or the symptoms of the disease.
  • reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
  • the term "therapeutic effect” refers to a therapeutic benefit and/or a prophylactic benefit as described herein.
  • a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
  • the articles “a” and “an” refer to one or to more than one (for example, to at least one) of the grammatical object of the article.
  • “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20-25 percent (%), for example, within 20 percent, 10 percent, 5 percent, 4 percent, 3 percent, 2 percent, or 1 percent of the stated value or range of values.
  • alkyl refers to straight chained and branched saturated hydrocarbon groups containing one to six carbon atoms.
  • C n means the alkyl group has “n” carbon atoms.
  • C 6 alkyl refers to an alkyl group that has 6 carbon atoms.
  • Ci-C 6 alkyl refers to an alkyl group having a number of carbon atoms encompassing the entire range (e.g., 1 to 6 carbon atoms), as well as all subgroups (e.g., 1 -6, 2-6, 1-5, 3-6, 1 , 2, 3, 4, 5, and 6 carbon atoms).
  • alkyl groups include, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl (2-methylpropyl), t-butyl (1 ,1 -dimethylethyl), and 3-methylpentyl.
  • an alkyl group can be an unsubstituted alkyl group or a substituted alkyl group.
  • alkylene refers to an alkyl group having a substituent.
  • an alkylene group can be -CH 2 CH 2 - or -CH 2 -.
  • C r means the alkylene group has “n” carbon atoms.
  • Ci- 6 alkylene refers to an alkylene group having a number of carbon atoms encompassing the entire range, as well as all subgroups, as previously described for “alkyl” groups.
  • a Co alkylene indicates a direct bond.
  • an alkylene group can be an unsubstituted alkylene group or a substituted alkylene group. Particular substitutions on the alkylene group can be specified, e.g., alkylene-CN, or the like.
  • alkyne or “alkynyl” used herein refers to an unsaturated aliphatic group analogous in length and possible substitution to an alkyl group described above, but that contains at least one triple bond.
  • alkynyl includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl), and branched alkynyl groups.
  • a straight chain or branched alkynyl group can have six or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • C 2 -C 3 includes chains having a number of carbon atoms encompassing the entire range (e.g., 2 to 6 carbon atoms), as well as all subgroups (e.g., 2-6, 2-5, 2-4, 3-6, 2, 3, 4, 5, and 6 carbon atoms).
  • C 3 -C 6 includes chains having a number of carbon atoms encompassing the entire range (e.g., 3 to 6 carbon atoms), as well as all subgroups (e.g., 3- 6, 3-5, 3-4, 3, 4, 5, and 6 carbon atoms).
  • an alkynyl group can be an unsubstituted alkynyl group or a substituted alkynyl group.
  • haloalkyl refers to an alkyl group substituted with one or more halogen substituents.
  • Ci-C 6 haloalkyl refers to a Ci-C 6 alkyl group substituted with one or more halogen atoms, e.g., 1 , 2, 3, 4, 5, or 6 halogen atoms.
  • a Cohaloalkyl refers simply to a halo substituent.
  • Non-limiting examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl groups.
  • halo or halogen refers to fluorine, chlorine, bromine, or iodine.
  • hydroxyalkyl refers to an alkyl group substituted with one or more hydroxyl substituents.
  • Ci-C 3 hydroxyalkyl refers to a Ci-C 6 alkyl group substituted with one or more hydroxyl groups, e.g., 1 , 2, 3, 4, 5, or 6 hydroxyl groups.
  • a Cohydroxyalkyl refers to a hydroxyl group.
  • Non-limiting examples of hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl groups.
  • alkoxy refers to a straight or branched hydrocarbon group which has an oxygen atom as the point of attachment.
  • the alkoxy group can further comprise additional oxygen atoms in the hydrocarbon backbone, e.g., 1 , 2, 3, or 4 additional oxygen atoms.
  • carbocycle or “carbocyclyl” or “cycloalkyl” refers to a cyclic hydrocarbon group containing three to eight carbon atoms (e.g., 3, 4, 5, 6, 7, or 8 carbon atoms).
  • n-membered carbocycle means the carbocycle group has “n” carbon atoms.
  • 5-membered carbocycle refers to a carbocycle group that has 5 carbon atoms in the ring.
  • 6- to 8-membered carbocycle refers to carbocycle groups having a number of carbon atoms encompassing the entire range (e.g., 6 to 8 carbon atoms), as well as all subgroups (e.g., 6-7, 6-8, 7-8, 6, 7, and 8 carbon atoms).
  • carbocycle groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • a carbocycle group can be an unsubstituted carbocycle group or a substituted carbocycle group.
  • the carbocycle groups described herein can be isolated or fused to another carbocycle group.
  • the carbocycles described herein can have a fused, bridged, or spiro structure.
  • each of the carbocycle groups can contain three to eight carbon atoms unless specified otherwise.
  • heterocycle or “heterocycloalkyl” is defined similarly as carbocycle, except the ring contains one to four heteroatoms independently selected from oxygen, nitrogen, and sulfur.
  • heterocycle refers to a ring containing a total of three to eight atoms (e.g., three to five, or five to eight), of which 1 , 2, 3 or 4 of those atoms are heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, and the remaining atoms in the ring are carbon atoms.
  • heterocycle groups include azetidine, piperdine, piperazine, pyrazolidine, tetrahydrofuran, tetrahydropyran, dihydrofuran, morpholine, quinuclidine, and the like.
  • Heterocycle groups can be saturated or partially unsaturated ring systems optionally substituted with, for example, one to three groups, such as halo, Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 alkoxy, Ci- 6 haloalkoxy, CN, and SO 2 Ci- 3 alkyl.
  • Other substituents are also contemplated, including C 0-3 alkylene-halo, C 0.3 alkylene-CN, C 0.3 alkylene-NH 2 , C 0-3 alkyleneOH, and C 0-3 alkylene-O-Ci. 3 alkyl.
  • Heterocycloalkyl groups optionally can be further N- substituted with alkyl, alkylene-OH, alkylenearyl, and alkyleneheteroaryl.
  • the heterocycle groups described herein can be isolated or fused to another heterocycle group and/or a carbocycle group. When a heterocycle group is fused to another heterocycle group, then each of the heterocycle groups can contain three to ten total ring atoms, and one to four heteroatoms.
  • aryl refers to a monocyclic aromatic group, such as phenyl. Unless otherwise indicated, an aryl group can be unsubstituted or substituted with one or more, and in particular one to four groups independently selected from, for example, halo, alkyl, alkenyl, OCF 3 , N0 2 , CN, NC, OH, alkoxy, amino, CO 2 H, CO 2 alkyl, aryl, and heteroaryl.
  • Aryl groups can be isolated (e.g., phenyl) or fused to another aryl group (e.g., naphthyl, anthracenyl), a cycloalkyl group (e.g., tetraydronaphthyl), a heterocycloalkyl group, and/or a heteroaryl group.
  • aryl groups include, but are not limited to, phenyl, chlorophenyl, fluorophenyl, methylphenyl, methoxyphenyl, trifluoromethylphenyl, nitrophenyl, 2,4- methoxychlorophenyl, and the like.
  • heteroaryl refers to a monocyclic aromatic ring having 5 to 6 total ring atoms, and containing one to four heteroatoms selected from nitrogen, oxygen, and sulfur atom in the aromatic ring. Unless otherwise indicated, a heteroaryl group can be unsubstituted or substituted with one or more, and in particular one to four, substituents selected from, for example, halo, alkyl, alkenyl, OCF 3 , NO 2 , CN, NC, OH, alkoxy, amino, CO 2 H, CO 2 alkyl, aryl, and heteroaryl.
  • substituents are also contemplated, including C 0 3 alkylene-halo, C 0 3 alkylene-CN, C 0 3 alkylene-NH 2 , C 0 3 alkylene-OH, and C 0 3 alkylene-O- Ci- 3 alkyl.
  • the heteroaryl group is substituted with one or more of alkyl and alkoxy groups.
  • heteroaryl groups include, but are not limited to, thienyl, furyl, pyridyl, pyrrolyl, oxazolyl, triazinyl, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.
  • substituents when used to modify a chemical functional group, refers to the replacement of at least one hydrogen radical on the functional group with a substituent.
  • substituents can include, but are not limited to, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, oxy, alkoxy, heteroalkoxy, ester, thioester, carboxy, cyano, nitro, amino, amido, acetamide, and halo (e.g., fluoro, chloro, bromo, or iodo).
  • the substituents can be bound to the same carbon atom or to two or more different carbon atoms.
  • Compounds of the present disclosure can exist in particular geometric or stereoisomeric forms having one or more asymmetric carbon atoms.
  • the present disclosure contemplates such forms, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the disclosed compounds.
  • Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are intended for inclusion herein.
  • the term “pharmaceutically acceptable” means that the referenced substance, such as a compound of the present disclosure, or a formulation containing the compound, or a particular excipient, are safe and suitable for administration to a patient or subject.
  • pharmaceutically acceptable excipient refers to a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.
  • the compounds disclosed herein can be as a pharmaceutically acceptable salt.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benef it/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1 -19, which is incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutamate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, peroxine sodium
  • Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base.
  • suitable base include, but are not limited to, alkali metal, alkaline earth metal, aluminum salts, ammonium, N + (Ci- 4 alkyl) 4 salts, and salts of organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N’- dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2- hydroxyethyljamine, procaine, dibenzylpiperidine, dehydroabietylamine, N,N’- bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acids such as lysine and arginine.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
  • Formula (I) Compounds: [0036] Provided herein are compounds, or salts thereof, for use in the disclosed methods having a structure of Formula (I): wherein ring B is a 5-12 membered monocyclic, bicyclic, or bridged nitrogen-containing heterocycle comprising 0-1 additional ring heteroatoms selected from N, O, and S,
  • R 1 is either a part of a bicyclic or bridged heterocycle or is H, Ci- 6 alkyl, SO 2 R 6 , or C(O)R 3 ;
  • ring A is a C 6 aryl or 5-7 membered heteroaryl comprising 1-4 ring heteroatoms selected from N, O, and S, and is optionally substituted with 1 -3 R 3 groups;
  • X is Ci- 5 alkylene, Co- 5 alkylene-Y or Y-Ci- 5 alkylene-Y; each Y is independently C(O), OC(O), C(O)NR 4 , NR 4 C(O), or SO 2 ;
  • R 2 is C 6 -ioaryl, 5-10 membered heteroaryl comprising 1-4 ring heteroatoms selected from N, O, and S, or 5-12 membered monocyclic or bicyclic carbocycle or heterocycle, wherein the heterocycle comprises 1-4 ring heteroatoms selected from N, O, and S, and R 2 is optionally substituted with 1-3 R 3 groups; each R 3 , when present, is independently selected from Ci.
  • Ar is 3-8-membered carbocycle or heterocycle, wherein the heterocycle comprises 1 - 4 ring heteroatoms selected from N, O, and S; C 6 -ioaryl; or 5-10 membered heteroaryl comprising 1-4 ring heteroatoms selected from N, O, and S and Ar is optionally substituted with 1 -3 groups independently selected from halo, Ci-ealkyl, Ci-shaloalkyl, Ci-salkoxy, Ci- ehaloalkoxy, CN, and SO 2 Ci- 3 alkyl; each R 4 and R 5 is independently H, Ci-salkyl, or C(O)Ci-6alkyl; each R 6 is independently Ci-ealkyl, Ci-ehaloalkyl, or Ar; each R 7 is independently H or Ci- 6 alkyl; m is 0-2; and n is 0-2, with the proviso that the compound is not In some cases, the structure of Formula (I) has a structure
  • R 1 is H or Me.
  • ring A comprises phenyl or pyridyl and is optionally substituted with 1 -2 groups selected from fluoro and chloro.
  • ring A is phenyl substituted with 1 fluoro.
  • ring A is phenyl substituted with 1 chloro.
  • ring A is pyridyl substituted with 1 fluoro.
  • ring A is pyridyl substituted with 1 chloro.
  • ring A is unsubstituted phenyl.
  • ring A is unsubstituted pyridyl.
  • X can be Ci-salkylene, Co-salkylene-Y or Y-Ci-salkylene-Y; and each Y is independently C(O), OC(O), C(O)NR 4 , NR 4 C(O), or SO 2 .
  • X is Y (i.e., no alkylene linker is present).
  • X comprises an alkylene linker to ring A (i.e., comprises a Ci- 5 alkylene moiety, with or without a Y group present).
  • X is Co- 5 alkylene-Y or Y-C 0-5 alkylene-Y.
  • Y is NR 4 C(O) or C(O)NR 4 and R 4 is H or Me.
  • X is CH 2 C(O), OC(O), or NR 4 C(O) (e.g., R 4 is H).
  • X is OC(O).
  • X is NHC(O).
  • X is CH 2 C(O).
  • R 2 can be Ce-ioaryl, 5-10 membered heteroaryl comprising 1 -4 ring heteroatoms selected from N, O, and S, or 5-12 membered monocyclic or bicyclic carbocycle or heterocycle, wherein the heterocycle comprises 1 -4 ring heteroatoms selected from N, O, and S, and R 2 is optionally substituted with 1-3 R 3 groups.
  • R 2 is phenyl, e.g., phenyl substituted with 1 -2 fluoro and/or chloro groups.
  • R 2 is pyridyl, pyrazine, pyrimidine, thiophene, benzothiophene, benzofuranyl, piperidinone, indole, indazole, benzodiazole, benzoimidazole, benzoxazole, benzothiazole, indolizine, imidazo- [1 ,2-a]pyridine, imidazo-[1 ,5-a]pyridine, or imidazo-[1 ,2-a]pyrimidine.
  • R 2 is unsubstituted.
  • R 2 is substituted with 1 R 3 .
  • R 2 is substituted with 2 R 3 .
  • R 2 is substituted with 3 R 3 .
  • R 2 is selected from the group consisting of
  • the structure of Formula (I) is a structure of Formula (IA) wherein Y’ is CH 2 , NR 4 or O, and each R 8 is independently H or Me, or both R 8 taken together with the carbon to which they are attached form a cyclopropyl ring.
  • the structure of Formula (IA) can be structure can alternatively various cases, the structure of
  • Formula (IA) can be wherein one R 8 is H and the other Me. In some cases, each R 8 is Me.
  • both R 8 together with the carbon to which they are attached form a cyclopropyl ring.
  • Some specifically contemplated compounds of Formula (I) include those as shown in Table A below, or a pharmaceutically acceptable salt thereof.
  • a compound of the disclosure is one as listed in Table B, or a pharmaceutically acceptable salt thereof.
  • the compound of the disclosure is a compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of
  • A is a 4-10 membered heterocycle comprising 1 to 3 ring heteroatoms selected from N, O, and S, optionally substituted with 1 to 3 R 3 ;
  • Y is Co-salkylene, Co. 6 alkylene-0-Co-6alkylene, C 0.6 alkylene-NR N , Co-salkylene-S0 2 , CO, CO2, or CONH, wherein Co- 6 alkylene is optionally substituted with 1 or 2 R 4 ; each R 1 is independently halo, -O-CH 2 -Csaryl-(OCH2CH2)p-OR 5 , or -O-CH 2 -Het-
  • OCH 3 wherein Het is a 6-membered heteroaryl comprising 2 ring N atoms; one R 2 is H and the other is H, CN, COOCi-salkyl, CONHCi-ealkyl, SO2CH3, or O- propargyl;
  • R 3 is Cvsalkyl, halo, Coealkylene-OH, Co- 6 alkylene-0-propargyl, propargyl, or Co- 6 alkylene-NR N R N ; each R 4 is independently F, OH, or OCi- 6 alkyl, or two R 4 together with the carbon atom to which they are attached form cyclopropyl;
  • R 5 is Ci- 6 alkyl or propargyl; each R N is independently H or Ci- 6 alkyl; n is 1 -3; and p is 0-2; with the proviso that
  • Y is CH 2 , O, or NR N , then one R 2 is H and the other R 2 is not H; or membered heterocycle comprising 1 to 3 ring heteroatoms selected from N, O, and S, optionally substituted with 1 or 2 R 3 ;
  • Y is Co-salkylene, Co. 6 alkylene-0-Co-6alkylene, C 0.6 alkylene-NR N , Co-salkylene-S0 2 , CO 2 -, or CONH-, wherein Co- 6 alkylene is optionally substituted with 1 or 2 R 4 ; each R 1 is independently halo, -O-CH 2 -C6aryl-(OCH 2 CH2) P -OR 5 , or -O-CH 2 -Het-
  • OCH 3 wherein Het is a 6-membered heteroaryl comprising 2 ring N atoms; one R 2 is H and the other is H, CN, COOCi-salkyl, CONHCi-ealkyl, SO 2 CH 3 , or O- propargyl;
  • R 3 is Ci- 6 alkyl; each R 4 is independently F or OR 3 ;
  • R 5 is Ci- 6 alkyl or propargyl
  • R N is H or Ci- 6 alkyl; n is 1 -3; and p is 0-2; with the proviso that
  • Y is CH 2 , O, or NR N , then one R 2 is H and the other R 2 is not H; or hen A does not comprise
  • A is a 4-10 membered heterocycle comprising 1 to 3 ring heteroatoms selected from N, O, and S, optionally substituted with 1 or 2 R 3 ;
  • Y is C 0-6 alkylene, C 0-6 alkylene-O, Co- 6 alkylene-0-Co- s alkylene, C 0-6 alkylene-NR 3 , C o - 6 alkylene-SO 2 , CO 2 -, or CONH-, wherein Co ealkylene is optionally substituted with 1 or 2 R 4 ; each R 1 is independently halo, -O-CH 2 -C 6 aryl-(OCH 2 CH 2 ) P -OR 5 , or -O-CH 2 -Het- (OCH 3 ), wherein Het is a 6-membered heteroaryl comprising 2 ring N atoms; one R 2 is H and the other is H, CN, COOCi. 6 alkyl, CONHCi. 6 alkyl, SO 2 CH 3 , or O- propargyl;
  • R 3 is H or Ci- 6 alkyl; each R 4 is independently F or OR 3 ;
  • R 5 is Ci-salkyl or propargyl; n is 1 -3; and p is 0-2; with the proviso that
  • the compound of Formula (1-1 ) has the structure of Formula (la-1 ) or (lb-1 ): compound of Formula (1-1 ) has the structure of Formula (la-1 ). In some cases, the compound of Formula (1-1 ) has the structure of Formula (lb-1 ).
  • the compound of Formula (l)-1 has the structure of Formula (lc-1 ) or (Id-1): compound of Formula (1-1 ) has the structure of Formula (lc-1 ). In some cases, the compound of Formula (1-1 ) has the structure of Formula (Id-1 ).
  • A comprises a 4 membered heterocycle. In some cases, A comprises a 5 membered heterocycle. In some cases, A comprises a 6 membered heterocycle. In some cases, A comprises a 7 membered heterocycle. In some cases, A comprises an 8 membered heterocycle. In some cases, A comprises a 9 membered heterocycle. In some cases, A comprises a 10 membered heterocycle. In some cases, A comprises a 4-, 6-, 8-, or 10-membered heterocycle comprising 1 or 2 ring heteroatoms selected from N and O. In some cases, A comprises an 8-membered heterocycle comprising 1 or 2 ring heteroatoms selected from N and O. In some cases, A is substituted with 1 to 3 R 3 . In some cases, A is substituted with 1 or 2 R 3 . In some cases, A is unsubstituted.
  • A comprises In some cases, A comprises In some cases, A comprises In some cases, A In some cases, A comprises some cases, A
  • Y is C 0.6 alkylene, Co-6alkylene-0-Co. 6 alkylene (e.g., Co-salkylene-O), C 0 -6alkylene-NR N , C 0 -6alkylene-SO 2 , CO, CO 2 -, or CONH-.
  • Y is Co. 6 alkylene, Co-6alkylene-0-Co-6alkylene (e.g., Co-6alkylene-0), C 0 -salkylene-NR N , C 0 -6alkylene-SO 2 , CO 2 -, or CONH-.
  • Y is C o alkylene (i.e., a bond).
  • Y is Ci. 6 alkylene, Ci-ealkylene-O, or Ci-6alkylene-NR N .
  • Y is C 0.6 alkylene-O or C 0.6 alkylene-NR N . In some cases, Y is C 0 - 6 alkylene-O. In some cases, Y is Ci 6 alkylene-O. In some cases, Y is Ci 6 alkylene-NR N . In some cases, Y is NH or O. In some cases, Y is NH. In some cases, Y is O.
  • the Ci- 6 alkylene of a Y moiety is unsubstituted. In some cases, Ci- 6 alkylene is substituted with 1 or 2 R 4 . In some cases, Ci- 6 alkylene is substituted with 1 R 4 .
  • each R 1 is independently halo. In some cases, each R 1 is independently -O-CH 2 -C 6 aryl-(OCH2CH2)p-OR 5 or -O-CH 2 -Het-(OCH 3 ), wherein Het is a 6- membered heteroaryl comprising 2 ring N atoms. In some cases, each R 1 is independently - O-CH 2 -C 6 aryl-(OCH2CH2)p-OR 5 . In some cases, each R 1 is independently -O-CH 2 -Het- (OCH 3 ).
  • At least one R 1 is halo. In some cases, at least one R 1 is F. In some cases, each R 1 is F. In some cases, at least one R 1 is -O-CH2-C 6 aryl-(OCH 2 CH2)p- OR 5 . In some cases, at least one R 1 is -O-CH 2 -Het. In some cases, Het comprises 2- pyrimidyl or 5-pyrimidyl optionally substituted with OMe. In some cases, Het comprises 2- pyrimidyl. In some cases, Het comprises 5-pyrimidyl. In some cases, Het is unsubstituted. In some cases, Het is substituted with OMe.
  • both R 2 are H.
  • one R 2 is H and the other is CN, COOCi- 6 alkyl, CONHCi- 6 alkyl, SO 2 CH 3 , or O-propargyL
  • one R 2 is H and the other is CN.
  • one R 2 is H and the other is COOCH 3 or CONHCH3.
  • one R 2 is H and the other is COOCH3.
  • one R 2 is H and the other is CONHCH3.
  • one R 2 is H and the other is SO2CH3.
  • one R 2 is H and the other is O-propargyL
  • R 3 is Ci- 6 alkyl, halo, Co- 6 alkylene-OH, C 0-6 alkylene-O-propargyl, propargyl, or Co- 6 alkylene-NR N R N .
  • R 3 is Ci- 6 alkyl.
  • R 3 is C1- 6 alkyl .
  • R 3 is halo.
  • R 3 is fluoro.
  • R 3 is C o - 6 alkylene-OH.
  • R 3 is Cialkylene-OH.
  • R 3 is C 0 alkylene-OH, i.e., R 3 is OH.
  • R 3 is C o 6 alkylene-O-propargyl. In some cases, R 3 is C 2 alkylene-O-propargyl. In some cases, R 3 is propargyl. In some cases, R 3 is Co-6alkylene- NR N R N . In some cases, R 3 is Cialkylene-NR N R N . In some cases, R 3 is Coalkylene-NR N R N , i.e., R 3 is NR N R N .
  • each R 4 is independently F, OH, or OCi- 6 alkyl, or two R 4 together with the carbon atom to which they are attached form cyclopropyl.
  • R 4 is F, OH, or OCH3.
  • R 4 is F.
  • R 4 is OH or OCH 3 .
  • R 4 is OH.
  • R 4 is OCH 3 .
  • two R 4 together with the carbon atom to which they are attached form cyclopropyl.
  • R 5 is methyl. In some cases, R 5 is propargyl.
  • each R N is independently H or Ci- 6 alkyl. In some cases, R N is H. In some cases, R N is Ci- 6 alkyl. In some cases, R N is methyl.
  • p is 0. In some cases, p is 1 . In some cases, p is 2.
  • n is 1 . In some cases, n is 2. In some cases, n is 3.
  • ring A comprises a 4- to 8-membered monocyclic or bicyclic carbocycle or heterocycle optionally substituted with 1 -3 R 2 groups, wherein the heterocycle comprises a ring nitrogen or oxygen, or both; each R 1 is independently Ci- 6 alkyl, O-Ci- 6 alkyl, C 0-3 alkylene-halo, O-Ci- 3 alkylene- halo,C 0-3 alkylene-CN, C 0-3 alkylene-NR 4 2 ,
  • each R 2 is independently halo, OH, Ci- 6 alkyl, Ci. 6 haloalkyl, Ci.
  • each R N is independently H or Ci- 6 alkyl
  • each R 4 is independently H, Ci. 6 alkyl, or C(O)Ci- 6 alkyl
  • each R 5 is independently Ci ealkyl, Ci-ehaloalkyl, or Ar
  • each R 6 is independently H or C-i 6 alkyl ;
  • Ar is 3-8-membered carbocycle or heterocycle, wherein the heterocycle comprises 1 - 4 ring heteroatoms selected from N, O, and S; C 6 -ioaryl; or 5-10 membered heteroaryl comprising 1-4 ring heteroatoms selected from N, O, and S and Ar is optionally substituted with 1 -3 groups independently selected from halo, Ci. 6 alkyl, Ci. 6 haloalkyl, Ci. 6 alkoxy, Cv 6 haloalkoxy, CN, and SO 2 Ci. 3 alkyl; m is 0-2; n is 0-3; and p is 0-2.
  • one of X and Y is O and the other is CH 2 or CH 2 CH 2 , or X is null or CH 2 and Y is CH 2 O, and each R 2 is independently halo, Ci-ealkyl, or Co- 6 alkylene- N(R N ) 2 .
  • the compound has a structure of Formula (I I-2) : structure of Formula
  • one of X and Y is O and the other is CH 2 or CH 2 CH 2 , or X is null or CH 2 and Y is CH 2 O.
  • each R 2 is independently halo, Ci. 6 alkyl, or -N(R N ) 2 .
  • one of X and Y is O and the other is CH 2 or CH 2 CH 2 , or X is null or CH 2 and Y is CH 2 O and each R 2 is independently halo, Ci. 6 alkyl, or -N(R N ) 2 .
  • Y is O. In some cases, Y is CH 2 or CH 2 CH 2 . In some cases, Y is CH 2 . In some cases, Y is CH 2 CH 2 . In some cases, Y is CH 2 O. [0074] In some cases, X is CH 2 . In some cases, X is CH 2 CH 2 . In some cases, X is O.
  • R 2 is halo. In some cases, R 2 is F. In some cases, R 2 is Ci- 6 alkyl. In some cases, R 2 is methyl. In some cases, R 2 is Co- 6 alkylene-N(R N ) 2 . In some cases, R 2 is C 0 alkylene-N(R N ) 2 , i.e. , N(R N ) 2 . In some cases, R 2 is NH 2 . In some cases, R 2 is OH. In some cases, R 2 is Ci- e haloalkyl. In some cases, R 2 is Ci- S hydroxyalkyl.
  • R 3 is halo. In some cases, R 3 is F.
  • m is 0 or 1 . In some cases, m is 0. In some cases, m is 1 . In some cases, m is 2.
  • n is 0. In some cases, n is 1 , 2, or 3. In some cases, n is 1 . In some cases, n is 2. In some cases, n is 3.
  • the compound has a structure of Formula (111-2):
  • Q 1 is C 0-3 alkylene-NR 6 2 . In some cases, Q 1 is Ci- 3 alkylene-NR 6 2 .
  • Q 1 is CH 2 NH 2 .
  • Q 1 is a 4- to 8-membered monocyclic or bicyclic carbocycle or heterocycle optionally substituted with 1 -3 R 2 groups, wherein the heterocycle comprises a ring nitrogen or oxygen.
  • Q 1 comprises a quinuclidine, piperidine, pyrrolidine, azetidine, or cyclobutane moiety.
  • Q 1 is substituted with 1 -3 R 2 groups.
  • ring A comprises a quinuclidine, piperidine, pyrrolidine, 8- azabicyclo[3.2.1]octane, 6-azabicyclo[3.1 .1]heptane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, furan, pyran, oxepin, morpholine, or thiomorpholine moiety.
  • ring A is substituted with 1 -3 R 2 groups.
  • ring A is i , , is . in some cases, ring A is / In some cases, ring A is . In some cases, ring
  • R 1 is F, Cl, OH, OMe, OiPr, OBn, O-cyclopropyl, CF 3 , OCF 3 , CN, SO 2 Me, S0 2 -cyclopropyl, SO 2 iPr, oxo, imidazolyl, triazolyl, pyrrolidinyl, pyrrolidinonyl, thiadiazolyl, methyl-thiadiazolyl, trifluoromethyl- thiadiazolyl, oxadiazolyl, methyl-oxadiazolyl, trifluoromethyl- oxadiazolyl, or phenyl.
  • R 1 is F or Cl.
  • R 1 is F.
  • R 1 is Cl.
  • p is 0. In some cases, p is 1 . In some cases, p is 2.
  • X is O, NR 2 , or CR A R B ;
  • R A is hydrogen, OH, or O-Ci-3alkyl
  • R B is hydrogen
  • R A and R B together are oxo
  • R 1 is hydrogen, Ci- 6 alkyl, C 0-3 haloalkyl, O-Ci- 3 haloalkyl,C 0-3 alkylene-CN, C 0-3 alkylene-NR N 2 , C 0 6 alkylene-OR N , Co 6 alkylene- C(O)OR N , C 0 6 alkylene-C(O)N(R N ) 2 , or Co 6 alkylene-SO p R N ; each R N is independently hydrogen or Ci. 6 alkyl, and p is 0-2;
  • R 2 is hydrogen, Ci. 6 alkyl, C 3 -6alkynyl, or Ci- 6 alkylene-SO2-Ci- 3 alkyl; each R 3 is independently halo;
  • R 4 is hydrogen, OH, halo, or Co-ealkylene-NR 6 R 7 ; each R 5 is independently hydrogen, C-i- 3 alkyl, C 0-3 hydroxyalkyl, or halo;
  • R 6 is hydrogen
  • R 7 is hydrogen, C ⁇ alkynyl, Co- 3 alkylen C(O)Ci-6haloalkyl; or
  • R 6 and R 7 together with the nitrogen to which they are attached form a 4- to 6- membered heterocycle having 0-1 additional ring heteroatoms selected from N, O, and S and optionally substituted with 1 , 2, or 3 groups independently selected from halo and oxo; m is 1 or 2; n is 0-3; and r is 1 or 2.
  • X is O, NR 2 , or CR A R B ;
  • R A is hydrogen, OH, or O-Ci- 3 alkyl
  • R B is hydrogen
  • R A and R B together are oxo
  • R 1 is hydrogen, Ci- 6 alkyl, C 0-3 haloalkyl, O-Ci- 3 haloalkyl,C 0-3 alkylene-CN, C 0-3 alkylene-NR N 2 , C 0-6 alkylene-OR N , C 0-6 alkylene- C(O)OR N , Co- 6 alkylene-C(0)N(R N ) 2 , or C 0-6 alkylene-SO p R N ; each R N is independently hydrogen or Ci- 6 alkyl, and p is 0-2;
  • R 2 is hydrogen, Ci- 6 alkyl, C 3.6 alkynyl, or Ci- 6 alkylene-SO 2 -Ci- 3 alkyl; each R 3 is independently halo;
  • R 4 is hydrogen, OH, halo, or C 0-6 alkylene-NR 6 R 7 ; each R 5 is independently hydrogen, Ci- 3 alkyl, or halo;
  • R 6 is hydrogen or Ci- 3 alkyl
  • R 7 is hydrogen, Ci- 3 alkyl, Ci- 3 haloalkyl, C 2-6 alkynyl, Ci- 3 alkylene-O-C 2-6 alkynyl, C o - 3 alkylene-SO 2 -Ci- 3 alkyl, Co- 3 alkylene-S0 2 -Ci- 3 haloalkyl, C(O)Ci- 6 alkyl, or C(0)Ci- 6 haloalkyl; or
  • R 6 and R 7 together with the nitrogen to which they are attached form a 4- to 6- membered heterocycle having 0-1 additional ring heteroatoms selected from N, O, and S and optionally substituted with 1 , 2, or 3 groups independently selected from halo and oxo; m is 1 or 2; n is 0-3; and r is 1 or 2.
  • X is O. In some cases, X is CR A R B . In some cases, X is CH 2 . In some cases, X is NR 2 .
  • R A is OH. In some cases, R A and R B together are oxo.
  • Y is Coalkylene. In some cases, Y is Ci-ealkylene. In some cases,
  • Y is Cialkylene. In some cases, Y is C 2 alkylene. In some cases, Y is C 3 alkylene.
  • ring A is a 3- to 5-membered carbocycle. In some cases, ring A is a 6- to 8-membered carbocycle. In some cases, ring A is a 3-membered carbocycle. In some cases, ring A is a 4-membered carbocycle. In some cases, ring A is a 5-membered carbocycle. In some cases, ring A is a 6-membered carbocycle. In some cases, ring A is a 7-membered carbocycle. In some cases, ring A is a 8-membered carbocycle. In some
  • R 1 is hydrogen. In some cases, R 1 is Ci- 6 alkyl, C 0-3 haloalkyl, O-Ci- 3 haloalkyl,C 0-3 alkylene-CN, C 0-3 alkylene-NR N 2 , C 0-6 alkylene-OR N , C 0-6 alkylene- C(O)OR N , Co- 6 alkylene-C(0)N(R N ) 2 , or Co- 6 alkylene-SO p R N .
  • R 1 is F, Cl, OH, OMe, OiPr, OBn, O-cyclopropyl, CF 3 , OCF 3 , CN, SO 2 Me, S0 2 -cyclopropyl, SO 2 iPr, oxo, imidazolyl, triazolyl, pyrrolidinyl, pyrrolidinonyl, thiadiazolyl, methyl-thiadiazolyl, trifluoromethyl- thiadiazolyl, oxadiazolyl, methyl-oxadiazolyl, trifluoromethyl- oxadiazolyl, or phenyl.
  • R 1 is F or Cl. In some cases, R 1 is F.
  • R 1 is hydrogen, Ci- 6 alkyl, C 0-3 haloalkyl, 0-Ci- 3 haloalkyl,C 0-3 alkylene-CN, C 0-3 alkylene-NR N 2 , C 0-6 alkylene-OR N , C 0-6 alkylene- C(O)OR N , C 06 alkylene-C(O)N(R N ) 2 , or Co 6 alkylene-SO p R N ; each R N is independently hydrogen or Ci. 6 alkyl, and p is 0-2.
  • At least one R N is hydrogen. In some cases, each R N is hydrogen. In some cases, at least one R N is Ci- 6 alkyl. In some cases, each R N is Ci- 6 alkyl.
  • R 2 is hydrogen. In some cases, R 2 is Ci- 6 alkyl, C 3.6 alkynyl, or Ci- 6 alkylene-SO 2 -Ci- 3 alkyl. In some cases, R 2 is CH 3 .
  • R 3 is fluoro
  • R 4 is hydrogen. In some cases, R 4 is OH. In some cases, R 4 is halo. In some cases, R 4 is F. In some cases, R 4 is Co-6alkylene-NR 6 R 7 . In some cases, R 4 is -CH 2 NH 2 , -CH 2 NHCH 3 , -CH 2 CH 2 NH 2 , -CH 2 CH(CH 3 )NH 2 , -CH 2 C(CH 3 ) 2 NH 2 , or -CH 2 CH 2 N(CH 3 ) 2 . In some cases, R 4 is NR 6 R 7 . In some cases, R 4 is Cialkylene-NR 6 R 7 .
  • R 4 is -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -NHCH 2 CF 3 , -NH-propargyl, -NHC(O)CH 3 , -NHC(O)CF 3 , -NHSO 2 CH 3 , -NHSO 2 CF 3 , or -NHCH 2 CH 2 SO 2 CH 3 .
  • R 4 is -NH 2 .
  • R 5 is hydrogen, Ci- 3 alkyl, or halo.
  • R 6 is hydrogen. In some cases, R 6 is Ci- 3 alkyl. In some cases, R 6 is methyl.
  • R 7 is hydrogen. In some cases, R 7 is Ci- 3 alkyl. In some cases, R 7 is methyl. In some cases, R 7 is ethyl. In some cases, R 7 is Ci- 3 haloalkyl. In some cases, R 7 is trifluoroethyl. In some cases, R 7 is C 2.6 alkynyl. In some cases, R 7 is propargyl. In some cases, R 7 is C 0-3 alkylene-SO 2 -Ci- 3 alkyl or C 0-3 alkylene-SO 2 -Ci- 3 haloalkyl. In some cases, R 7 is SO 2 -methyl or SO 2 CF 3 .
  • R 7 is C 2 alkylene-SO 2 -methyl. In some cases, wherein R 7 is C(O)Ci- 6 alkyl or C(0)Ci- 6 haloalkyl. In some cases, R 7 is C(O)CH 3 or C(O)CF 3 . In some cases, R 7 is hydrogen, Ci- 3 alkyl, Ci- 3 haloalkyl, C 2.6 alkynyl, Ci- 3 alkylene-O-C 2 .
  • R 6 and R 7 together with the nitrogen to which they are attached form a 4- to 6-membered heterocycle. In some cases, R 6 and R 7 together with the nitrogen to which they are attached form a heterocycle selected from , wherein N* indicates the nitrogen to which R 6 and R 7 are attached.
  • At least one R 5 is H. In some cases, each R 5 is hydrogen. In some cases, at least one R 5 is Ci- 3 alkyl. In some cases, at least one R 5 is methyl. In some cases, each R 5 is methyl. In some cases, at least one R 5 is halo. In some cases, at least one R 5 is fluoro. In some cases, each R 5 is fluoro.
  • R N is hydrogen. In some cases, R N is Ci. 6 alkyl. In some cases, R N is methyl.
  • n is 1 . In some cases, m is 2.
  • n is 0. In some cases, n is 1 . In some cases, n is 2. In some cases, n is 3.
  • p is 0. In some cases, p is 1 . In some cases, p is 2.
  • r is 1 . In some cases, r is 2. [0112] Specific compounds contemplated include those listed in Table A-3, or a pharmaceutically acceptable salt thereof:
  • the compounds described herein can be administered to a subject in a therapeutically effective amount, alone or as part of a pharmaceutically acceptable composition or formulation.
  • the compounds can be administered all at once, multiple times, or delivered substantially uniformly over a period of time. It is also noted that the dose of the compound can be varied over time.
  • a particular administration regimen for a particular subject will depend, in part, upon the compound, the amount of compound administered, the route of administration, and the cause and extent of any side effects.
  • the amount of compound administered to a subject e.g., a mammal, such as a human
  • Dosage typically depends upon the route, timing, and frequency of administration. Accordingly, the clinician titers the dosage and modifies the route of administration to obtain the optimal therapeutic effect, and conventional range-finding techniques are known to those of ordinary skill in the art.
  • the method comprises administering, for example, from about 0.1 mg/kg up to about 100 mg/kg of compound or more, depending on the factors mentioned above.
  • the dosage ranges from 1 mg/kg up to about 100 mg/kg; or 5 mg/kg up to about 100 mg/kg; or 10 mg/kg up to about 100 mg/kg.
  • Some conditions require prolonged treatment, which may or may not entail administering lower doses of compound over multiple administrations.
  • a dose of the compound is administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • the treatment period will depend on the particular condition and type of pain, and may last one day to several months.
  • Suitable methods of administering a physiologically acceptable composition such as a pharmaceutical composition comprising the compounds disclosed herein are well known in the art. Although more than one route can be used to administer a compound, a particular route can provide a more immediate and more effective reaction than another route. Depending on the circumstances, a pharmaceutical composition comprising the compound is applied or instilled into body cavities, absorbed through the skin or mucous membranes, ingested, inhaled, and/or introduced into circulation.
  • a pharmaceutical composition comprising the agent orally, through injection by intravenous, intraperitoneal, intracerebral (intra- parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means, by sustained release systems, or by implantation devices.
  • intracerebral intra- parenchymal
  • intracerebroventricular intramuscular
  • intra-ocular intraarterial
  • intraportal intralesional, intramedullary
  • intrathecal intraventricular
  • transdermal subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means, by sustained release systems, or by implantation devices.
  • the compound is administered regionally via intrathecal administration, intracerebral (intra-parenchymal) administration, intracerebroventricular administration, or intraarterial or intravenous administration feeding the region of interest.
  • the composition is administered locally via implantation of a membrane, sponge, or another appropriate material onto which the desired compound has been absorbed or encapsulated.
  • the device is, in one aspect, implanted into any suitable tissue or organ, and delivery of the desired compound is, for example, via diffusion, timed-release bolus, or continuous administration.
  • the compound is, in various aspects, formulated into a physiologically acceptable composition
  • a carrier e.g., vehicle, adjuvant, or diluent.
  • the particular carrier employed is limited only by physico-chemical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.
  • Physiologically acceptable carriers are well known in the art.
  • Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U.S. Patent No. 5,466,468).
  • a pharmaceutical composition comprising the compound is, in one aspect, placed within containers, along with packaging material that provides instructions regarding the use of such pharmaceutical compositions.
  • such instructions include a tangible expression describing the reagent concentration, as well as, in certain embodiments, relative amounts of excipient ingredients or diluents (e.g., water, saline or PBS) that may be necessary to reconstitute the pharmaceutical composition.
  • excipient ingredients or diluents e.g., water, saline or PBS
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • Microorganism contamination can be prevented by adding various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example, sugars, sodium chloride, and the like.
  • Prolonged absorption of injectable pharmaceutical compositions can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration include capsules, tablets, powders, and granules.
  • the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
  • fillers or extenders as for example, starches, lactose, sucrose, mannitol, and silicic acid;
  • binders as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia;
  • humectants as for example, glycerol;
  • disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate;
  • solution retarders as for example, paraffin;
  • absorption accelerators as for example, quaternary ammonium compounds;
  • the dosage forms may also comprise buffering agents.
  • Solid compositions of a similar type may also be used as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art.
  • the solid dosage forms may also contain opacifying agents.
  • the solid dosage forms may be embedding compositions, such that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes.
  • the active compound can also be in micro-encapsulated form, optionally with one or more excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame seed oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • inert diluents commonly used in the art, such as water or other solvents, solub
  • the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compound, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances, and the like.
  • compositions for rectal administration are preferably suppositories, which can be prepared by mixing the compounds of the disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary room temperature, but liquid at body temperature, and therefore, melt in the rectum or vaginal cavity and release the active component.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary room temperature, but liquid at body temperature, and therefore, melt in the rectum or vaginal cavity and release the active component.
  • compositions used in the methods of the invention may be formulated in micelles or liposomes.
  • Such formulations include sterically stabilized micelles or liposomes and sterically stabilized mixed micelles or liposomes.
  • Such formulations can facilitate intracellular delivery, since lipid bilayers of liposomes and micelles are known to fuse with the plasma membrane of cells and deliver entrapped contents into the intracellular compartment.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
  • parenteral administration in an aqueous solution for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the frequency of dosing will depend on the pharmacokinetic parameters of the agents and the routes of administration.
  • the optimal pharmaceutical formulation will be determined by one of skill in the art depending on the route of administration and the desired dosage. See, for example, Remington’s Pharmaceutical Sciences, 18th Ed. (1990) Mack Publishing Co., Easton, PA, pages 1435-1712, incorporated herein by reference. Such formulations may influence the physical state, stability, rate of in vivo release and rate of in vivo clearance of the administered agents.
  • a suitable dose may be calculated according to body weight, body surface areas or organ size.
  • the precise dosage to be employed depends upon several factors including the host, whether in veterinary medicine or human medicine, the nature and severity of the condition, e.g., disease or disorder, being treated, the mode of administration and the particular active substance employed.
  • the compounds may be administered by any conventional route, in particular enterally, and, in one aspect, orally in the form of tablets or capsules.
  • Administered compounds can be in the free form or pharmaceutically acceptable salt form as appropriate, for use as a pharmaceutical, particularly for use in the prophylactic or curative treatment of a disease of interest. These measures will slow the rate of progress of the disease state and assist the body in reversing the process direction in a natural manner.
  • compositions and treatment methods of the invention are useful in fields of human medicine and veterinary medicine.
  • the subject to be treated is in one aspect a mammal.
  • the mammal is a human.
  • PAL photoaffinity labeling
  • BV2 cells were pre-treated with vehicle or Compound 1 (competitor, 10 pM) for 30 minutes and then photoaffinity labeling compound (PAL, 100 nM) was added for another 30 minutes. Cells were then washed, plates transferred to ice and irradiated with UV light for 10 minutes. After the crosslinking reaction, the cells were washed once with cold PBS and a cell scraper was used to collect cells. Pellets were washed three times with cold PBS and stored at -80 °C.
  • Proteins were precipitated using a mixture of methanol:chloroform:water (2:0.5:1 .3) and the resulting pellet resuspended in 800 pL of resuspension buffer (50 mM Tris-HCI, pH 8.0 and 1% SDS).
  • resuspended proteins were incubated with enzyme mix and incubated following the manufacturer’s (NEB) protocol. Biotinylated proteins were immunoprecipitated using streptavidin beads for 1 hour at room temperature. Bound proteins were eluted by incubating beads with 2x sample buffer containing TCEP at 100°C for 10minutes.
  • Figure 1 shows that a band running around 100 kDa could be competed by Compound 1 .
  • This band was in-gel digested with trypsin and mass spectrometry analysis identified CD68 as the potential enriched protein in the PAL sample.
  • samples were blotted with both a fluorescent streptavidin and an anti-CD68 antibody showing the overlap of the two signals ( Figure 1 ).
  • CD68 is known to be highly glycosylated.
  • a deglycosylation experiment was performed using EndoH and PNGaseF treatment of the cross-linked sample to determine whether the biotinylated protein (streptavidin signal) and CD68 signal still overlapped.
  • streptavidin and CD68 still overlapped perfectly, confirming the identity of the immunoprecipitated protein as CD68.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de modulation de CD68 ou de traitement de troubles associés à CD68, à l'aide d'un composé tel que présentement divulgué.
PCT/US2023/024906 2022-06-10 2023-06-09 Composés pour la modulation de cd68 et leurs utilisations Ceased WO2023239892A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263350955P 2022-06-10 2022-06-10
US63/350,955 2022-06-10

Publications (1)

Publication Number Publication Date
WO2023239892A1 true WO2023239892A1 (fr) 2023-12-14

Family

ID=87136721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/024906 Ceased WO2023239892A1 (fr) 2022-06-10 2023-06-09 Composés pour la modulation de cd68 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2023239892A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
EP2090576A1 (fr) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
EP2439202A1 (fr) * 2009-06-04 2012-04-11 Laboratorios SALVAT, S.A. Composés inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase de type 1
US20160207933A1 (en) * 2011-03-18 2016-07-21 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2019118528A1 (fr) 2017-12-12 2019-06-20 Arkuda Therapeutics Modulateurs de progranuline et leurs procédés d'utilisation
WO2020252222A1 (fr) 2019-06-12 2020-12-17 Arkuda Therapeutics Modulateurs de la progranuline et leurs procédés d'utilisation
WO2021081272A1 (fr) 2019-10-25 2021-04-29 Arkuda Therapeutics Modulateurs de la progranuline et leurs procédés d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
EP2090576A1 (fr) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
EP2439202A1 (fr) * 2009-06-04 2012-04-11 Laboratorios SALVAT, S.A. Composés inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase de type 1
US20160207933A1 (en) * 2011-03-18 2016-07-21 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2019118528A1 (fr) 2017-12-12 2019-06-20 Arkuda Therapeutics Modulateurs de progranuline et leurs procédés d'utilisation
WO2020252222A1 (fr) 2019-06-12 2020-12-17 Arkuda Therapeutics Modulateurs de la progranuline et leurs procédés d'utilisation
WO2021081272A1 (fr) 2019-10-25 2021-04-29 Arkuda Therapeutics Modulateurs de la progranuline et leurs procédés d'utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO., pages: 1435 - 1712
BANKERCHALMERS: "Pharmaceutics and Pharmacy Practice", 1982, J. B. LIPPINCOTT CO., pages: 238 - 250
LI LING ET AL: "Atorvastatin Inhibits CD68 Expression in Aortic Root Through a GRP78-Involved Pathway", CARDIOVASCULAR DRUGS AND THERAPY, KLUWER ACADEMIC PUBLISHERS, BOSTON, US, vol. 28, no. 6, 5 October 2014 (2014-10-05), pages 523 - 532, XP035410611, ISSN: 0920-3206, [retrieved on 20141005], DOI: 10.1007/S10557-014-6556-3 *
S. M. BERGE ET AL.: "describe pharmaceutically acceptable salts in detail in", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
TOISSEL: "ASHP Handbook on Injectable Drugs", 1986, pages: 622 - 630

Similar Documents

Publication Publication Date Title
JP7299372B2 (ja) シラノールベースの治療用ペイロード
CA3219236A1 (fr) Derives d'exatecan et conjugues anticorps-medicament de ceux-ci
US12186324B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2017210526A1 (fr) Méthode de traitement de la fibrose hépatique
CN111051328A (zh) 作为抗癌剂的环二核苷酸
US11052091B2 (en) BRK inhibitory compound
WO2015196071A1 (fr) Composés, compositions et procédés pour augmenter l'activité du cftr
CA2980395A1 (fr) Composes heterocycliques et leur utilisation dans la prevention ou le traitement d'infections bacteriennes
US20210163471A1 (en) Progranulin modulators and methods of using the same
CN111801322B (zh) 用于治疗中枢和周边神经系统病症的激酶抑制剂
US20230174548A1 (en) Symbiotic prodrugs for the treatment of cancer and other diseases
US10730832B2 (en) Aliphatic prolinamide derivatives
CN115066423B (zh) Pd-l1拮抗剂化合物
WO2023239892A1 (fr) Composés pour la modulation de cd68 et leurs utilisations
CN116178350A (zh) 一种天然来源大环内酯衍生物及其制备方法和作为抗肿瘤药物的应用
US11180499B2 (en) Phosphodiesterase inhibitors
US20230115534A1 (en) Progranulin modulators and methods of using the same
US20230406843A1 (en) Progranulin Modulators and Methods of Using the Same
WO2024226870A1 (fr) Modulateurs trpml1 tricycliques fusionnés et leurs procédés d'utilisation
HK40007630B (en) Aliphatic prolinamide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23738317

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23738317

Country of ref document: EP

Kind code of ref document: A1